Panacea
Biotec Ltd. (PBL) is delighted to announce the
collaboration with signing of two long term agreements with
Serum Institute of India Pvt. Ltd. (SII) and SII’s wholly owned subsidiary,
Bilthovan Biologicals B.V. (BBIO). Under the collaboration SII is entitled to manufacture & sell fully liquid Whole
cell Pertussis (wP) and Salk based Injectable Polio Vaccine (IPV) based
Hexavalent vaccine (DTwP-HepB-Hib-IPV) developed & commercialized by
Panacea Biotec, a first of its kind in this category.
Under
the collaboration, broadly the following will be achieved: -
Serum Institute of India will ensure supply of IPV
bulk to Panacea Biotec, an important constituent of the Hexavalent vaccine,
from its wholly owned subsidiary BBIO, a bioengineering and pharmaceutical
company, registered in The Netherlands having technology and expertise for
making the IPV, earlier possessed by only 3 other vaccine manufacturers in the
World.
In next 2 years both SII and PBL will work together to
get this wP-IPV based Hexavalent Vaccine introduced in the National
Immunization Program of Government of India anddeveloping countries by working
closely with key stakeholders including but not limited to National
Governments, World Health Organization(WHO), Global Alliance for Vaccines &
Immunization (GAVI), Bill and Melinda Gates Foundation (BMGF) and other United
Nation Agencies, etc.
Global
demand of IPV/ IPV containing vaccines is estimated to rise significantly from
~100 Million in the year 2020 till supply constraints remain, to 250-350 Million
doses every year starting 2022 depending upon a two or three dose schedule as
Strategic Advisory Group of Experts (SAGE) on Immunization in April 2017 has
recommended at least 2 doses of IPV in the routine Immunization schedule of the
countries post OPV withdrawal.
Here
it is important to note that there has been a global supply constraint of IPV
since early 2015 and only 52% of projected supply had been delivered to UN
agencies as a result of which 18 Countries could not introduce IPV in their
immunization & 15 had interruptions out of 70 IPV eligible countries
approved for GAVI support.
A beaming Mr Adar C. Poonawalla,
C.E.O. & Executive Director, Serum Institute of India, said, “It is an
historic deal where in two major vaccine Companies in India have come forward
to join hands to address unmet needs of both Private & Public Market
globally. With the convenience of ‘Six in one’ it has potential of over 250
million doses in next 3-4 years with a market size of over $1.25 Billion
annually.”
Mr R K Suri, Senior Advisor, who
orchestrated the mega deal between two big Vaccine players said, “It marks
beginning of a new Era in vaccine landscape and heralds a new business model,
‘Collaborate yet Compete!’.”
About Panacea Biotec:
Panacea Biotec Limited
is a leading research based biotechnology company with established research,
manufacturing and marketing capabilities. It is one of the largest
vaccine producers and Biotechnology Companies in India.
Panacea Biotec is the
first company to have developed World’s first fully-liquid Quadravalent Vaccine
Easyfour-TT (DTwP-Hib) Pentavalent Vaccine Easyfive-TT
(DTwP-HepB-Hib), monovalent Polio vaccine against Type 1 and Type 3 Polio virus
and World’s First Fully Liquid whole cell Pertussis (wP) based Hexavalent
Combination Vaccine, EasySix.TM
The Company is also
amongst the top 15 pharmaceutical companies (AIOCD AWACS-MAT MAR-2017) in its
represented market India and amongst top 60 pharmaceutical Companies in India.
The Company has been awarded with the prestigious “India Innovation Award
2016 – Top 50” by Clarivate Analytics.
The product portfolio of
includes highly innovative products in therapeutic areas of oncology, organ
transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases
and pediatric vaccines. It is working on a robust pipeline of high barrier to
entry generics products, thus leveraging its capabilities in the areas of
nanotechnology and platform drug delivery technologies like micro-particles,
liposomes, gastroretentive systems.
The Company has research
collaborations with leading national and international research organizations
and corporations. The company's state-of-the-art manufacturing facilities for
vaccines and pharmaceutical formulations comply with several leading regulatory
agencies worldwide. The company has around 2,500 employees including around 100
scientists working across 4 R&D centers of the Company.
About Serum Institute of India:
Serum Institute of India Pvt. Ltd. is now the world's largest vaccine
manufacturer by number of doses produced and sold globally (more than 1.3
billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus,
Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is
estimated that about 65% of the children in the world receive at least one
vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum
Institute are accredited by the World Health Organization, Geneva and are being
used in around 170 countries across the globe in their national immunization
programs, saving millions of lives throughout the world.
Serum Institute of India is ranked as India's No. 1 biotechnology
company, manufacturing highly specialized lifesaving biologicals like vaccines
using cutting edge genetic and cell based technologies, antisera and other
medical specialties.
Serum Institute of India was founded in 1966 by Dr. Cyrus Poonawalla
with the aim of manufacturing life-saving immuno-biologicals, which were in
shortage in the country and imported at high prices. Thereafter, several
life-saving biologicals were manufactured at prices affordable to the common
man and in abundance, with the result that the country was made self-sufficient
for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria,
Tetanus and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps
and Rubella) group of vaccines.
The Philanthropic philosophy of the company still not only exists but
has been proliferated to bring down the prices of newer vaccines such as
Hepatitis-B vaccine, Combination vaccine etc., so that not only Indian's, but
the entire under-privileged children of the world are protected from birth
onwards.
No comments:
Post a Comment